El nostre pipeline

Última actualizació, juliol 2022.

Molecule / Project
Indication
Expected Launch
Preclinical Phase Phase I Phase II Phase III Under Registration Geography
Lebrikizumab Atopic dermatitis
Late 2023
90 Under registration
EU EU
Tirbanibulin
Extended label 		Actinic keratosis
US 2024 / EU 2026
75 Fase3
U.S. U.S.
EU EU
Sarecycline Acne
2024
80 Fase3
China China
Efinaconazole Onychomycosis
2023
95 Under registration
EU EU
Anti-IL-1RAP mAb Autoinmune dermatology
TBD
30 Fase1
Worldwide Worldwide
IL-2 mu Fc Autoinmune dermatology
TBD
15 Preclinical Phase
Worldwide Worldwide *

Atopic dermatitis Lebrikizumab Late 2023 Under registration EU

Actinic keratosis Tirbanibulin
Extended label US 2024 / EU 2026 Fase3 U.S. EU

Acne Sarecycline 2024 Fase3 china

Onychomycosis Efinaconazole 2023 Under registration EU

Autoinmune dermatology Anti-IL-1RAP mAb TBD Fase1 worldwide

Autoinmune dermatology IL-2 mu Fc TBD Preclinical Phase worldwide_exchina ‏‏* Worldwide ex-Greater China